Public COA audit
Tirzepatide
Audited July 29, 2026
Several fields check out, but we found issues worth reviewing before you rely on this document.
- Legitimacy
- 92
- Confidence
- 93%
- Panels
- 2/7
- Purity (printed)
- 99.7%
Document details
Fields extracted from the certificate — not order or payment data.
- Batch / lot
- SNB64RZ
- Identity method
- FTIR (USP <197A>)
- Sample date
- 2026-03-13
- Issue date
- 2026-03-18
7-panel checklist
Had data + good, had data + bad, reported without pass/fail, or missing. Missing lowers thoroughness — you decide whether that panel matters; PeptIQ’s score still factors coverage.
2 of 7 present · 2 passed · 0 failed · 0 reported · 5 missing
Missing is a thoroughness gap — not automatically bad. PeptIQ’s legitimacy score still weighs panel coverage; you can down-weight panels that don’t matter for your use case.
Identity
Tested · passed · core
Compound identity confirmed (e.g. HPLC, mass spec).
FTIR sample spectrum confirms the presence of Tirzepatide with addition of excipient(s)/fillers
Purity
Tested · passed · core
Reported purity percentage for the analyte.
99.7%
Heavy metals
Not on this COA
Lead, arsenic, cadmium, mercury, or similar limits.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Microbial
Not on this COA
Bioburden / microbial limits testing.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Endotoxin
Not on this COA · core
LAL or chromogenic endotoxin assay.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Sterility
Not on this COA
Sterility testing where applicable.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Residual solvent / water
Not on this COA
Residual solvents or water content limits.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
How to read this
Had data · good
Panel present with a pass (or clear acceptance).
Had data · bad
Panel present with a fail — a concrete quality signal.
Had data · unclear
Value reported without an explicit pass/fail mark.
Missing
Not on this certificate. Lowers thoroughness; you decide if that panel matters for your use case. PeptIQ’s score still factors coverage.
Findings
Evidence-linked observations from this audit.
High HPLC purity achieved
99.7% purity by HPLC meets specification of ≥98%. This is normal for research-grade peptides.
Identity confirmed by FTIR
FTIR spectrum confirms Tirzepatide presence with excipients/fillers noted, consistent with formulated product.
Batch information complete
Lot number SNB64RZ clearly stated with BT Sample ID 005000039245195.
Testing dates reasonable
Sample tested 2026-03-13, report issued 2026-03-18 (5-day turnaround). Both dates are before today (2026-07-29).
Testing lab identified
BTLabs (West Palm Beach, FL) with contact information and dual scientist signatures (Andrea Castro, AS and Verna Zheng, AS).
Limited testing scope
COA explicitly states it does not provide information on particulate matter, microbial contamination, or endotoxins. No heavy metals, sterility, or residual solvent testing performed. This is disclosed upfront and is common for basic identity/purity testing.
Professional presentation
Document includes FTIR spectrum and HPLC chromatogram on page 2, supporting analytical claims. Dual-branded header (BTLabs and Finnrick) with verification URL provided.
Potency within specification
HPLC potency assay shows 66.3 mg (110.4% of labeled 60 mg), within the 90-110% specification range.
PeptIQ COA reports analyze document content and publicly verifiable lab signals. They are educational and not a guarantee of product quality, legality, or safety. Always consult a qualified professional before making health decisions. We never publish purchase prices, shipping details, or uploader identity.